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yocardial infarction (MI) leads to rapid necrosis of cardiac
yocytes in the ischemic heart. Despite aggressive primary
herapies to reconstitute blood supply and intense pharma-
ological approaches, prognosis remains poor, especially in
atients with large MI and severe left ventricular dysfunc-
ion. Mechanistically, large myocardial infarcts induce a
rocess termed “cardiac remodeling” that consists of mor-
hologic, histological, and molecular changes of both the
nfarcted and the non-infarcted myocardium (1). Ventricu-
ar remodelling is a strong prognostic determinant and
losely related to the incidence of arrhythmias and sudden
ardiac death (2). There is an extremely narrow time
indow to rescue viable myocardium, and in contrast to
ome rare exceptions in nature (3), activation of endogenous
ealing mechanisms is insufficient to maintain tissue integ-
ity and function. Thus, therapeutic approaches targeting
ealing mechanisms to prevent infarct expansion would be
f great value. An understanding of such mechanisms is
carce but important to develop novel strategies to prevent
evelopment of heart failure after MI.
See page 135
he transforming growth factor (TGF)- superfamily
nd MI. The TGF- superfamily of cytokines exerts im-
ortant functions in tissue homeostasis and adaptation by
egulating cell survival, proliferation, and differentiation.
embers include bone morphogenetic proteins, growth
ifferentiation factors (Gdf), anti-muellerian hormone, ac-
ivin, nodal, and TGF-. A variety of those members have
een described as playing a role in the development of
ardiac diseases; for instance, it is well known that TGF-
lays an important role in extracellular matrix formation,
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ürzburg, Germany; and the ‡Department of Molecular and Translational Thera-
eutic Strategies, Hannover Medical School, Hannover, Germany.specially collagen production. Animals with targeted dele-
ion of TGF- display reduced collagen deposition (4),
hereas an increase of TGF- in the heart results in cardiac
ypertrophy, interstitial fibrosis, and delayed wound-
ealing (5,6). Further TGF superfamily members are in-
reased during heart failure and contribute to cardiac re-
odelling, including activin (7) and Gdf8 (myostatin) (8).
he distant member Gdf15 protects the heart from isch-
mia/reperfusion injury, and consequently Gdf15-deficient
ice develop greater infarct sizes and display more cardio-
yocyte apoptosis in the infarct border zone (9).
In this issue of the Journal, Zaidi et al. (10) demonstrate
novel role for another member of the TGF- superfamily,
he growth Gdf5, for cardiac repair after MI. An important
nding of the authors is that Gdf5 exerts functional effects
n several different cells of the myocardium, including
ardiomyocytes, cardiac fibroblasts, and potentially cardiac
ndothelial cells. Loss of Gdf5 substantially increases col-
agen production and fibrosis in post-infarction hearts,
emonstrating key effects on cardiac fibroblasts. In addition,
df5 knockout (KO) mice show an increased rate of
ardiomyocyte apoptosis, a further hallmark of heart failure.
inally, the authors found a reduced vascular density in
nimals lacking Gdf5 after MI, although this was not
tudied in detail. Thus, Gdf5 might target at least
important cellular compartments of the heart, all of
onsiderable importance for ventricular remodelling pro-
esses. Cell type-specific KO strategies might further con-
ribute an understanding on the individual roles in selected
ardiac cell types. The authors detected Gdf5 expression in
ardiomyocytes and myofibroblasts but did not analyze its
xpression in cardiac endothelial cells. This is surprising
ecause Gdf5 was the first family member reported to may
ave a role in angiogenesis, and it was found that the
ddition of Gdf5 accelerated the migration of endothelial
ells, whereas it did not affect their proliferation. Additional
ffects of the lack of Gdf5 in cardiac endothelium might
esult in angiogenesis defects after MI that would further
ontribute to impaired cardiac healing. One might speculate
hether alterations in vascular density are mediated by
irect Gdf5 effects on endothelial cells or whether poten-
ially secondary paracrine effects are mediated by alterations
f cardiomyocytes and/or fibroblasts. Whether further cells
mportant for cardiac healing such as cardiovascular progen-
tor/stem cells or inflammatory cells are affected by Gdf5
lso remains to be determined.
echanism of action of Gdf5. Usually, a TGF- super-
amily ligand binds to a TGF- type II receptor, which
unctions as a serine/threonine receptor kinase. Upon re-
eptor activation, certain small mothers against decapen-
aplegic (Smads) are activated. The underlying molecular
echanisms that drive such phenotypic alterations by Gdf5
eficiency seem to be different in cardiomyocytes, cardiac
broblasts, and potentially endothelial cells. The Gdf5nduces p38-mitogen–activated protein kinase (MAPK)
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January 12, 2010:144–6 Gdf5 and Myocardial Infarctionhosphorylation in cardiac fibroblasts and thus limits colla-
en production, whereas no effects are observed in cardio-
yocytes. In contrast, Gdf5 has anti-apoptotic effects in
ardiomyocytes that are mediated by endogenous Smad4
and secondarily Smad1/5/8) but not p38-MAPK (Fig. 1).
nly low numbers of p-Smad1/5/8-positive cells are detect-
ble both in the scar tissue and viable myocardium after MI,
mplicating bone morphogenetic protein signaling as not
laying a crucial role in remodeling (11). In contrast, the
uthors observed a sustained increase of p-Smad1/5/8 ex-
ression in Gdf5-KO mice after MI, suggesting a superior
ole of Gdf5 in regulation of this group of Smad factors. In
ortic endothelial cells Gdf5 is pro-angiogenic at least in
art by plasminogen activator activity (12). However, the
pstream events that lead to different effects in different
ardiac cells are unclear and need further mechanistic
nalyses. In addition, it is unclear whether there is crosstalk
etween various members of the TGF- superfamily that
rive molecular and morphological changes after MI. In
ddition, information about the role of TGF- superfamily
ntagonists during infarct healing is missing. For instance,
embers of the DAN family of proteins (Ceberus, DAN,
remlin) might antagonize TGF- family members, and
AN indeed interacts with Gdf5 (13).
The authors’ findings of reduced blood pressure of
df5-KO mice are interesting but warrant further detailed
nalysis. The Gdf5 increases vascular endothelial growth
actor-A production (14), which augments nitric oxide
elease from the endothelium (15). This might contribute to
he strong differences in overall blood pressure between
ild-type and Gdf5-KO animals.
df5: potential therapeutic approaches. The idea to use
df5 for therapeutic approaches is not entirely new and has
een applied to induce formation and healing of tendons or
ones (16,17), protect neurons in Parkinson’s disease (18),
r improve erectile dysfunction (19). The detrimental effects
f the lack of Gdf5 on outcome after MI suggest therapeutic
Figure 1 Scheme of the Potential Underlying Mechanisms and
Functional Consequences of Gdf5 Deficiency After My
Col  collagen; Gdf5  growth differentiation factor 5; MAPK  mitogen-activated
NO  nitric oxide; Smad  small mothers against decapentaplegic; VEGF  vascueneficial effects with this factor for cardiac healing. Futuretudies need to test transgenic overexpression or pharmaco-
ogical strategies that increase Gdf5 concentration in the
eart after MI for therapeutic use. This would be of
onsiderable interest, because the authors identified Gdf5 to
onfer anti-apoptotic effects on cardiomyocytes, and further
ata suggest angiogenic and anti-fibrotic characteristics,
mportant to prevent ventricular remodeling. In conclusion,
aidi et al. (10) provided new insight in healing mecha-
isms of the infarcted heart; approaches using Gdf5 might
ranslate into new clinical translational strategies for
ost-MI treatment.
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